Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.75.

Several equities research analysts have issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group cut their price target on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $10.06 on Friday. The stock has a 50 day moving average price of $11.47 and a 200 day moving average price of $9.85. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $25.00. The firm has a market capitalization of $57.95 million, a P/E ratio of -0.39 and a beta of 0.46.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same quarter last year, the business posted ($16.50) earnings per share. As a group, sell-side analysts forecast that Atara Biotherapeutics will post -10.39 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $53,000. FMR LLC lifted its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics during the second quarter valued at about $79,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.